S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News

$8.17
+0.06 (+0.74%)
(As of 09/26/2023 ET)
Compare
Today's Range
$8.06
$8.39
50-Day Range
$8.11
$12.27
52-Week Range
$4.07
$12.43
Volume
1.55 million shs
Average Volume
1.61 million shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
63.2% Upside
$13.33 Price Target
Short Interest
Healthy
9.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

672nd out of 963 stocks

Pharmaceutical Preparations Industry

308th out of 451 stocks


AUPH stock logo

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

AUPH Price History

AUPH Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital
Nasdaq EM Asia Utilities Large
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+63.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-108,180,000.00
Pretax Margin
-44.42%

Debt

Sales & Book Value

Annual Sales
$134.03 million
Book Value
$2.85 per share

Miscellaneous

Free Float
137,255,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
1.24
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Peter S. Greenleaf M.B.A. (Age 53)
    Pres, CEO & Director
    Comp: $1.34M
  • Mr. Joseph M. Miller CPAMr. Joseph M. Miller CPA (Age 49)
    Chief Financial Officer
    Comp: $791.92k
  • Mr. Matthew Maxwell Donley M.B.A.Mr. Matthew Maxwell Donley M.B.A. (Age 54)
    Exec. VP of Operations & Strategy
    Comp: $811.82k
  • Mr. Stephen P. Robertson (Age 41)
    Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $739.68k
  • Dr. Volker Knappertz D.Sc. (Age 58)
    M.D., Exec. VP of R&D
    Comp: $742.85k
  • Mr. James Archie Harrell Jr. (Age 53)
    Head of Investor Relations
  • Mr. Fran Lynch
    VP of Sales
  • Mr. Michael R. MartinMr. Michael R. Martin (Age 51)
    Chief Bus. Officer
  • Ms. Sue Evans
    Sr. VP of Global Regulatory Affairs
  • Mr. Scott Habig (Age 63)
    Chief Commercial Officer













AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1 year price targets for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $12.00 to $15.00. On average, they anticipate the company's stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2023?

Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH stock has increased by 89.1% and is now trading at $8.17.
View the best growth stocks for 2023 here
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.12. The biotechnology company earned $41.49 million during the quarter, compared to analysts' expectations of $37.90 million. Aurinia Pharmaceuticals had a negative net margin of 45.42% and a negative trailing twelve-month return on equity of 18.05%. The firm's revenue for the quarter was up 47.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.25) EPS.

What ETFs hold Aurinia Pharmaceuticals' stock?

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings?

Aurinia Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$160.00 million, compared to the consensus revenue estimate of $154.35 million.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.81%), State Street Corp (1.84%), Goldman Sachs Group Inc. (1.22%), Renaissance Technologies LLC (1.07%), Geode Capital Management LLC (0.98%) and Northern Trust Corp (0.70%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $8.17.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.17 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

The company employs 300 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -